Autres langues Rhythm Pharmaceuticals, Inc.

Actions

RYTM

US76243J1051

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 02/05/2024			Varia. 5j.	Varia. 1 janv.
40,98 ^USD	-1,09%		+7,42%	-10,85%

30/04	Rhythm Pharmaceuticals, Inc. annonce la publication des résultats de l'étude de phase 2 sur le setmelanotide pour le traitement de l'obésité hypothalamique dans le Lancet Diabetes & Endocrinology	CI
18/04	RHYTHM PHARMACEUTICALS, INC. : Opinion positive de Wells Fargo Securities	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology	30/04
Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in the Lancet Diabetes & Endocrinology	30/04
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024	24/04
Rhythm Pharmaceuticals Announces New Employment Inducement Grants	16/04
Rhythm Pharmaceuticals to Sell $150 Million in Series A Convertible Preferred Stock	01/04
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing	01/04
Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, C2 Life Sciences, Llc, Perceptive Discovery ID LP	01/04
Rhythm Pharmaceuticals Doses First Patients in Phase 1 Trial of Potential Obesity Therapy	25/03
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist	25/03
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist	25/03
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist	25/03
Rhythm Pharmaceuticals Insider Sold Shares Worth $735,600, According to a Recent SEC Filing	22/03
Rhythm Pharmaceuticals Insider Sold Shares Worth $707,005, According to a Recent SEC Filing	22/03
Perceptive Advisors Engages in Discussion with Rhythm Pharmaceuticals	20/03
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	20/03
Rhythm Pharmaceuticals Insider Sold Shares Worth $627,520, According to a Recent SEC Filing	20/03
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	20/03
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	20/03
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	20/03
Rhythm Pharmaceuticals Announces New Employment Inducement Grants	11/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Rhythm Pharmaceuticals, Inc.

Actions

RYTM

US76243J1051

Autres langues

Filtres